3 COVID Stocks to Fight Omicron
With the COVID-19 pandemic surging back in intensity again due to the spread of the omicron variant, investors might be wondering what to do next. Three of our Foolish contributors have singled out companies that they expect will be leading the charge to protect us from the coronavirus over the next several years -- and that will likely outperform the market as they do so. Here's why they like Pfizer (NYSE: PFE), AstraZeneca (NASDAQ: AZN), and Novavax (NASDAQ: NVAX).
image source: Getty Images
George Budwell (Pfizer): Pfizer's stock is up by 61.8% so far this year, crushing the broader market due to the massive commercial success of Comirnaty, the COVID-19 vaccine it developed in partnership with BioNTech. Through the first nine months of 2021, Comirnaty racked up a whopping $24.3 billion in sales. Pfizer expects the vaccine to ultimately haul in more than $36 billion for the whole of 2021.
Source Fool.com
